Supernus Pharma (NASDAQ: SUPN) reported Q2 EPS of $0.40, $0.08 worse than the analyst estimate of $0.48. Revenue for the quarter came in at $165.5 million versus the consensus estimate of $154.3 million.

GUIDANCE:

Supernus Pharma sees FY 2025 revenue of $670-700 million, versus the consensus of $636.4 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.